Lebecque P, Vliers S, De Saint-Moulin T, Godding V
Pneumologie Pédiatrique, Cliniques St-Luc, Université Catholique de Louvain, Bruxelles, Belgique.
Rev Mal Respir. 1994;11(1):47-50.
The duration of action of inhaled formoterol, a new long-acting beta-2-agonist, was compared to inhaled salbutamol and placebo in a double-blind, randomized, cross-over study in 16 children (8-12 years old) with stable moderate to serve asthma. Mean baseline FEV1 was 68 +/- 8% predicted. On the 4 study days, baseline FEV1 was within 15% of the FEV1 on visit 1. Two-three days apart, each patient inhaled either placebo, salbutamol (200 micrograms) formoterol (12 or 24 micrograms). FEV1 and PEF were measured repeatedly during 8 and 12 hours respectively. After formoterol, improvement over placebo remained significant at 8 hours for FEV1 (p = 0.006) and 12 hours for PEF (p = 0.01). When compared to salbutamol, it was significant at 8 hours for PEF (p = 0.03). There were no significant differences in lung function when comparing the 12 micrograms and 24 micrograms doses of formoterol. Side-effects were minimal.
在一项针对16名（8至12岁）患有稳定的中度至重度哮喘的儿童的双盲、随机、交叉研究中，将新型长效β2受体激动剂吸入用福莫特罗的作用持续时间与吸入用沙丁胺醇和安慰剂进行了比较。平均基线第一秒用力呼气量（FEV1）为预测值的68±8%。在4个研究日，基线FEV1在第1次就诊时FEV1的15%范围内。每隔两到三天，每位患者吸入安慰剂、沙丁胺醇（200微克）或福莫特罗（12或24微克）。分别在8小时和12小时内重复测量FEV1和呼气峰值流速（PEF）。使用福莫特罗后，与安慰剂相比，FEV1在8小时时改善仍显著（p = 0.006），PEF在12小时时改善显著（p = 0.01）。与沙丁胺醇相比，PEF在8小时时差异显著（p = 0.03）。比较12微克和24微克剂量的福莫特罗时，肺功能无显著差异。副作用极小。
